By SaiyanMed Research Team · Updated 5 November 2026 · For in-vitro research use only
RESEARCH USE ONLY — PROFESSIONAL LABORATORY USE. This article is for qualified laboratory personnel carrying out in-vitro assays or institutionally approved laboratory animal studies. It is not a home-use, personal-use, human-use, or veterinary-use guide. The information below must not be used as an administration, formulation, reconstitution, or dosing plan. Zenagamtide (formerly amycretin) is an investigational compound. Its safety and efficacy have not been approved for marketing by the FDA or other regulators for any indication. Clinical trial results are summarized here as published research data, not as medical advice.
Quick answer
Zenagamtide (formerly known as amycretin; development code NNC0487-0111 on several ClinicalTrials.gov records) is an investigational unimolecular peptide agonist of both the glucagon-like peptide-1 (GLP-1) receptor and amylin receptors, developed by Novo Nordisk. Separate clinical programs evaluate once-weekly subcutaneous and once-daily oral formulations in overweight/obesity and type 2 diabetes research settings [Novo US ADA 2026]. A Phase 3 obesity programme branded AMAZE has been initiated, including head-to-head subcutaneous work versus semaglutide (AMAZE 7) and an oral tablet trial (AMAZE 9) [Novo Q1 2026; NCT07668414; NCT07720271; Novo Q3 2026].
Zenagamtide is not the same molecule as mono-amylin analogues such as petrelintide, eloralintide, or cagrilintide, and it is not the same as the two-drug combination CagriSema (cagrilintide + semaglutide).
Why the name changed from amycretin
Older peer-reviewed papers and 2025 company materials use the research name amycretin. By mid-2026, Novo Nordisk’s U.S. communications present the same unimolecular GLP-1/amylin peptide agonist as zenagamtide, explicitly noting it is “also known as amycretin” [Novo US ADA 2026]. ADA 2026 materials likewise frame zenagamtide as formerly known as amycretin (poster metadata cited in secondary science-hub listings).
Practical search tip for labs and librarians: treat zenagamtide, amycretin, and NNC0487-0111 as linked names for one development candidate when reconciling literature, registry entries, and any future research-lot paperwork — not as three different peptides. A rename does not change the underlying investigational status: there is still no marketing authorization.
Proposed redirect for SaiyanMed SEO: `/what-is-amycretin/` → `/what-is-zenagamtide/` (this hub), with the rename covered in this section so legacy SERP queries land on a single canonical page.
Receptor class: GLP-1 + amylin in one molecule
What “unimolecular dual agonist” means
Sponsor framing describes zenagamtide/amycretin as a single peptide engineered to agonize GLP-1 and amylin receptors together [Novo US ADA 2026; Novo GlobeNewswire 20 Jun 2025]. That architecture is distinct from:
| Approach | Example (research context) | How pathways are engaged |
|---|---|---|
| Unimolecular dual | Zenagamtide | One peptide sequence designed for GLP-1 + amylin receptor agonism |
| Two-drug combination / FDC | CagriSema | Separate cagrilintide (amylin analogue) + semaglutide (GLP-1 RA) |
| Mono-amylin analogue | Petrelintide, eloralintide, cagrilintide (mono programs) | Amylin-pathway peptide without built-in GLP-1 agonism in the same molecule |
| Dual/triple incretin (different class) | Tirzepatide (GIP/GLP-1); retatrutide (GIP/GLP-1/glucagon) | No amylin receptor as the second/third public headline target |
Why developers discuss both pathways
GLP-1 receptor agonists and amylin-pathway agonists are often described as having complementary effects on glycemic and body-weight biology in research literature, which is why combination and unimolecular dual programs exist [Novo US ADA 2026]. That mechanistic story explains pipeline design. It is not a license to claim zenagamtide is “better than” any approved medicine, or to use RUO material for personal weight loss.
Amylin receptors form when the calcitonin receptor (CTR) partners with a RAMP (AMY1/AMY2/AMY3 complexes) — the same high-level receptor biology reviewed for other amylin analogues on SaiyanMed’s petrelintide and eloralintide hubs. Assay-specific EC50 tables for zenagamtide were not pulled from an open primary pharmacology paper for this draft; do not invent selectivity rankings.
Oral vs subcutaneous research programs
Novo Nordisk is advancing both administration concepts for the same dual-agonist peptide biology [Novo US ADA 2026]:
| Program theme | Route (as studied) | Public early evidence snapshot | Phase 3 obesity example |
|---|---|---|---|
| Injectable weekly | Once-weekly subcutaneous | Lancet Ph1b/2a overweight/obesity [Lancet abstract]; Ph2 T2D ADA 2026 [Novo US] | AMAZE 7 vs semaglutide [NCT07668414] |
| Oral daily | Once-daily oral tablet | Phase 1 oral overweight/obesity data in Lancet (company summary) [GlobeNewswire 20 Jun 2025] | AMAZE 9 oral tablets [NCT07720271; Novo Q3 2026] |
The Phase 2 type 2 diabetes dose-finding record NCT06542874 itself includes both subcutaneous and oral NNC0487-0111 arms [CT.gov]; the June 2026 Novo U.S. release focused on the subcutaneous dose-finding results presented at ADA 2026 [Novo US ADA 2026]. Expert commentary after EASD 2026 also notes subcutaneous and oral arms within that broader T2D Phase 2 effort [touchENDOCRINOLOGY].
RUO note: clinical “tablet vs pen” research design is not a reconstitution recipe and does not imply that research powders are interchangeable with clinical-trial drug product.
Phase 1b/2a obesity signals (amycretin)
Every figure below is a trial-reported outcome under the stated analysis. None of it is a dosing schedule, eligibility recommendation, or product claim for research vials.
Subcutaneous Ph1b/2a (Lancet abstract + sponsor summary)
Design highlights from the open Lancet abstract [Lancet]:
- Randomised, placebo-controlled phase 1b/2a study of subcutaneous amycretin in adults aged 18–55 with BMI 27.0–39.9 kg/m² at a single centre (San Antonio, TX, USA).
- Registered as NCT06064006.
- 125 participants randomly allocated (amycretin n=101; placebo n=24).
- Primary endpoint: number of treatment-emergent adverse events (safety/tolerability) — not weight loss.
- Relative body-weight change was a secondary endpoint.
- Parts included single ascending dose and multiple ascending / dose-response maintenance concepts up to 60 mg over treatment durations up to 36 weeks.
Estimated mean body-weight change (amycretin vs placebo) as reported in the abstract and mirrored in Novo’s 20 June 2025 release [Lancet abstract; GlobeNewswire 20 Jun 2025]:
| Maintenance / escalation concept | Treatment duration | Amycretin mean % weight change | Placebo mean % weight change |
|---|---|---|---|
| Up to 60 mg (Part B) | 36 weeks | −24.3% | −1.1% |
| 20 mg maintenance (Part C) | 36 weeks | −22.0% | +1.9% |
| 5 mg maintenance (Part D) | 28 weeks | −16.2% | +2.3% |
| 1.25 mg maintenance (Part E) | 20 weeks | −9.7% | +2.0% |
Sponsor footnote on the table: figures reflect an analysis “if all people adhered to treatment” (planned schedule without discontinuations) [GlobeNewswire 20 Jun 2025]. The abstract also notes a large number of withdrawals, many for reasons unrelated to TEAEs [Lancet abstract] — so these early-phase estimates must not be treated as Phase 3-confirmed magnitude.
Most common TEAEs were gastrointestinal, mostly mild to moderate and resolving by end of study [Lancet abstract].
Oral Phase 1 overweight/obesity (company / Lancet oral paper summary)
Novo’s 20 June 2025 release summarizing the companion Lancet oral first-in-human paper reports [GlobeNewswire 20 Jun 2025]:
- Once-daily oral amycretin Phase 1 in 144 people with overweight or obesity; treatment up to 12 weeks.
- Mean body-weight change after 12 weeks: −10.4% (escalation up to 50 mg) and −13.1% (escalation up to 2×50 mg) versus −1.2% placebo.
- TEAEs mostly gastrointestinal, mild to moderate, dose-proportional; no new safety signals reported in that summary.
Gap flag: the oral Lancet abstract page timed out during this draft’s fetch pass — numbers above are from the sponsor press summary of that paper. Prefer full-text / open abstract verification before promoting oral figures to “abstract-confirmed” status.
Phase 2 type 2 diabetes signals (zenagamtide — ADA 2026)
Design (as publicly described)
Novo Nordisk’s 5 June 2026 U.S. release describes a 36-week, randomised, double-blind, placebo-controlled, dose-finding Phase 2 evaluation of six once-weekly subcutaneous zenagamtide doses (0.4–40 mg) versus matched placebo in 262 adults with type 2 diabetes inadequately controlled (A1C 7.0–10.0%) on metformin ± SGLT2 inhibitor [Novo US ADA 2026]. The registry record for this dose-finding program is NCT06542874 (NNC0487-0111 SC and oral arms; completed) [CT.gov].
Baseline characteristics reported for the ADA subcutaneous presentation: male 66%; mean age 57.1 years; A1C 7.8%; body weight 99.2 kg; 40% on SGLT2 inhibitor [Novo US ADA 2026].
Primary endpoint: change in A1C to week 36. Key supportive secondary: body-weight change (stated as meeting significance for doses 1.5 mg and greater) [Novo US ADA 2026].
Design caveat from the sponsor: fixed-dose-escalation; if the planned dose was not tolerated, treatment was permanently discontinued [Novo US ADA 2026]. Higher-dose groups had short maintenance exposure (e.g., 20 mg for 8 weeks; 40 mg for 4 weeks) [Novo US ADA 2026].
Efficacy table (sponsor ADA 2026 press)
On-treatment without rescue medication; ANCOVA as described by Novo [Novo US ADA 2026]:
| Endpoint (wk 36) | 0.4 mg | 1.5 mg | 5 mg | 10 mg | 20 mg | 40 mg | Pooled placebo |
|---|---|---|---|---|---|---|---|
| A1C change, %-points (baseline 7.8%) | −0.91 | −1.31 | −1.00 | −1.41 | −1.64 | −1.71 | −0.14 |
| Body-weight change, % (baseline 99.2 kg) | −4.35 | −7.62 | −8.19 | −12.92 | −13.13 | −14.60 | −2.10 |
Additional sponsor-reported supportive figures [Novo US ADA 2026]:
- Estimated mean A1C change “up to −1.71%” at 40 mg; ETD vs placebo −1.56% (95% CI −2.05, −1.07); p<0.0001.
- Dose–response model estimate up to −1.8% A1C (ETD −1.58; 95% CI −2.08, −1.08) and up to −14.5% body weight (ETD −11.81; 95% CI −15.37, −8.25) at 40 mg.
- Up to 89.1% of participants on zenagamtide achieved A1C <7%; up to 76.2% achieved ≤6.5%.
- Time in range 70–180 mg/dL up to 91.5% at 40 mg (stated above the >70% international target across all doses investigated).
- No apparent weight-loss plateau at week 36 with higher doses (sponsor interpretation).
Most common adverse events: gastrointestinal; majority mild to moderate; profile described as consistent with other incretin and amylin-based therapies [Novo US ADA 2026].
Label clearly: company press / congress presentation figures — not a completed Phase 3 label claim. Graded AE tables by dose were not reproduced in the open press text used here.
Based on these results, Novo stated plans to initiate a Phase 3 zenagamtide program in adults with type 2 diabetes in H2 2026 [Novo US ADA 2026].
Phase 3 AMAZE program
Program initiation
Novo’s Q1 2026 company announcement states that the zenagamtide AMAZE Phase 3 programme was initiated within obesity [Novo Q1 2026]. Q3 2026 IR adds that the AMAZE 9 Phase 3 trial with oral zenagamtide was initiated in September [Novo Q3 2026].
Initiation ≠ approval. No Phase 3 efficacy toplines for AMAZE were verified for this draft.
AMAZE 7 — subcutaneous vs semaglutide
From ClinicalTrials.gov [NCT07668414]:
| Field | Public value |
|---|---|
| Official title | Efficacy and Safety of Zenagamtide s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Obesity (AMAZE 7) |
| Status | Recruiting (as of fetch for this draft) |
| Phase | 3 |
| Estimated enrollment | 650 |
| Start | 2026-09-22 (actual) |
| Primary completion / completion | 2028-10-10 (estimated) |
| Design | Randomised, parallel, quadruple masking; zenagamtide vs two semaglutide dose comparator arms with matched placebos |
| Primary outcome | Relative change in body weight, week 0 to 84 |
| Population notes | Overweight/obesity; excludes diabetes history / HbA1c ≥6.5% per listed criteria |
AMAZE 9 — oral tablets
From ClinicalTrials.gov [NCT07720271]:
| Field | Public value |
|---|---|
| Official title | Efficacy and Safety of Once-daily Oral Zenagamtide in Participants With Obesity (AMAZE 9) |
| Status | Recruiting (as of fetch for this draft) |
| Phase | 3 |
| Estimated enrollment | 950 |
| Primary outcome | Relative change in body weight, baseline to week 76 |
| Arms | Oral zenagamtide (5 dose levels) vs matched placebo, once daily |
Other AMAZE-numbered obesity studies appear in registry searches (research pack notes NCT07668401, NCT07861100, etc.); cite each record individually when expanding the map — do not invent enrollment or endpoint numbers for unfetched IDs.
How zenagamtide differs from cagrilintide, petrelintide, and eloralintide
All of the following engage amylin-pathway biology in some way, but they are not interchangeable reference standards.
| Dimension | Zenagamtide | Cagrilintide | Petrelintide | Eloralintide |
|---|---|---|---|---|
| Public MoA headline | Unimolecular GLP-1 + amylin RA [Novo US] | Long-acting amylin analogue (major combo = CagriSema) | Long-acting human amylin analogue (Zealand/Roche) | Selective long-acting amylin RA (Lilly) |
| Built-in GLP-1 agonism in same molecule? | Yes (sponsor framing) | No (GLP-1 comes from partnered semaglutide in CagriSema) | No | No |
| Sponsor | Novo Nordisk | Novo Nordisk | Zealand + Roche | Eli Lilly |
| Common codes | NNC0487-0111; former name amycretin | AM833 (historical) | ZP8396 | LY3841136 |
| SaiyanMed reading | This hub | Product / cluster; vs Elo | What is petrelintide | What is eloralintide |
Cross-trial % weight loss is not a ranking. Populations (T2D yes/no), durations, estimands, escalation rules, and whether GLP-1 activity is co-packaged differ. A −24.3% Ph1b/2a amycretin secondary endpoint cannot be ranked against petrelintide ZUPREME-1 or eloralintide Phase 2/3 figures as if they were head-to-head arms.
How zenagamtide differs from CagriSema (one molecule vs two)
CagriSema is Novo Nordisk’s investigational combination of the amylin analogue cagrilintide with the GLP-1 receptor agonist semaglutide (fixed-dose / co-administered development). Peer-reviewed Phase 3 obesity evidence includes the REDEFINE 1 program published in NEJM [NEJM]. Novo’s Q3 2026 IR discusses continued CagriSema obesity/T2D readouts and U.S. launch preparation for early 2027 pending approval [Novo Q3 2026].
Zenagamtide aims at overlapping pathway themes (GLP-1 + amylin) but as a single peptide, with both injectable and oral research formulations [Novo US ADA 2026]. Manufacturing, PK, and titration stories therefore differ from a two-API combination — expert commentary after EASD 2026 explicitly contrasts unimolecular dual agonism with CagriSema-style co-formulation [touchENDOCRINOLOGY].
For labs: do not treat a vial labelled “zenagamtide/amycretin” as chemically equivalent to a cagrilintide + semaglutide mixture, and do not invent a SaiyanMed “CagriSema vial” from this page.
Related reading: eloralintide vs cagrilintide, cagrilintide RUO product, planned `/what-is-cagrisema/` hub (not yet live at draft time).
Research / analytical identity notes
Why a vial label is not identity
“Zenagamtide,” “amycretin,” and “NNC0487-0111” on a lyophilized powder do not prove equivalence to Novo’s clinical-trial drug product. Dual-agonist peptides can fail by wrong sequence, incomplete modification, isomer content, aggregation, or simple mislabeling. Cake appearance is not an analytical method.
Minimum COA packet (research buyer checklist)
| Item | Why it matters |
|---|---|
| Lot-matched COA | Must match the vial lot — not a “representative” PDF |
| RP-HPLC / UPLC purity + chromatogram | Area-% under a stated method; inspect shoulders |
| Intact-mass LC-MS | Observed vs theoretical mass for the intact modified peptide |
| Peptide content / counterion / water | Separates peptide mass from salt and residual solvent |
| Third-party testing when available | Reduces conflict of interest vs in-house-only sheets |
| Traceability | Manufacture/test dates, method IDs, lab identity |
For complex modified peptides, HPLC area-% without mass identity is incomplete — the same quality philosophy used on SaiyanMed’s petrelintide and eloralintide overviews.
Handling themes (no recipes)
Lyophilized peptides are commonly stressed by moisture, heat, light, and repeated freeze–thaw after reconstitution. Follow the batch COA and your institution’s validated procedures. This article does not provide diluent volumes, concentrations, injection instructions, titration schedules, or study protocols.
Stock status on SaiyanMed
No catalog SKU is claimed in this draft. Educational hub first; any future RUO listing requires supplier COA review and explicit go-ahead. Related amylin-pathway RUO tools already on catalog: eloralintide, cagrilintide. Contact research support for notify-if-stock only — do not assume inventory from this article.
Myth vs evidence
| Myth | Evidence-based correction |
|---|---|
| “Zenagamtide and amycretin are different drugs.” | Novo presents zenagamtide as also known as / formerly amycretin — same unimolecular dual-agonist program [Novo US ADA 2026]. |
| “Unimolecular dual = CagriSema.” | CagriSema is two components (cagrilintide + semaglutide); zenagamtide is one peptide [NEJM CagriSema; Novo US]. |
| “−24.3% means Phase 3–confirmed and every dose.” | Early Ph1b/2a secondary endpoint at up to 60 mg / 36 weeks under an adherence-style estimand; primary endpoint was safety [Lancet abstract]. |
| “AMAZE started, so it is approved.” | Still investigational; Phase 3 initiation ≠ marketing authorization [Novo Q1 2026]. |
| “Same as petrelintide / eloralintide.” | Those are mono-amylin analogues from other (or different) programs; zenagamtide adds GLP-1 agonism in one molecule [Petrel hub; Elo hub]. |
| “RUO vials are for personal weight loss.” | Explicitly out of scope for this page and for RUO supply. |
Glossary
- Unimolecular dual agonist: One peptide engineered to engage two receptor systems (here GLP-1 and amylin).
- Amycretin: Former research name for zenagamtide.
- NNC0487-0111: Novo development code appearing on ClinicalTrials.gov records for this program.
- AMAZE: Novo Phase 3 obesity program name for zenagamtide.
- CagriSema: Investigational cagrilintide + semaglutide combination (two APIs).
- Estimand / adherence analysis: Precise definition of the treatment effect being estimated; early amycretin weight tables include an “if all adhered” framing in sponsor materials.
- RUO: Research Use Only — not for human or veterinary administration.
- COA: Certificate of Analysis for a specific lot.
FAQ
What is zenagamtide?
Zenagamtide is an investigational unimolecular GLP-1 and amylin receptor agonist peptide developed by Novo Nordisk, also known as amycretin. It is being studied in subcutaneous and oral forms for obesity and type 2 diabetes research programs and is not an approved medicine [Novo US ADA 2026].
Is zenagamtide the same as amycretin?
Yes in development identity: Novo’s 2026 communications present zenagamtide as also known as / formerly amycretin [Novo US ADA 2026]. Literature searches should use both names.
What is NNC0487-0111?
NNC0487-0111 is the Novo Nordisk development code used on ClinicalTrials.gov for the dose-finding type 2 diabetes study and related records that map to this program [NCT06542874].
Is zenagamtide FDA-approved?
No. Sponsor materials describe it as investigational and under clinical trial development [Novo US ADA 2026].
How does zenagamtide work in research descriptions?
It is described as a single peptide that agonizes GLP-1 and amylin receptors, aiming to combine complementary pathway biology in one molecule [Novo US ADA 2026]. That is pharmacology context, not a use instruction.
What were the Phase 2 type 2 diabetes results?
In the ADA 2026 subcutaneous dose-finding presentation, week-36 A1C change reached about −1.71%-points at 40 mg versus −0.14% placebo (baseline 7.8%), and body-weight change reached about −14.6% versus −2.1% placebo, with gastrointestinal events the most common adverse events [Novo US ADA 2026].
What is the AMAZE program?
AMAZE is Novo Nordisk’s Phase 3 obesity programme for zenagamtide. Public examples include AMAZE 7 (once-weekly SC vs semaglutide; primary weight at week 84) and AMAZE 9 (once-daily oral; primary weight at week 76) [NCT07668414; NCT07720271; Novo Q3 2026].
How is zenagamtide different from CagriSema?
CagriSema combines two medicines (cagrilintide + semaglutide). Zenagamtide is one dual-agonist peptide [NEJM; Novo US].
How does it differ from petrelintide or eloralintide?
Petrelintide and eloralintide are investigational mono-amylin analogues (Zealand/Roche and Lilly, respectively). Zenagamtide adds GLP-1 agonism in the same molecule [Petrel; Elo].
Does SaiyanMed sell zenagamtide?
Not as a listed catalog SKU at the time of this draft. This page is research education. Request notify-if-stock after COA review; related RUO amylin tools: eloralintide, cagrilintide.
Can I use these trial percentages as a personal protocol?
No. Trial figures are published research data under specific protocols. This page provides no dosing, reconstitution, or titration guidance.
Are oral and injectable zenagamtide the same research material?
Clinical programs study both routes of the same dual-agonist concept [Novo US ADA 2026]. Research-chemical lots are not clinical-trial drug product; identity must be proven by lot-matched analytics.
Key takeaways
- Zenagamtide (formerly amycretin; code NNC0487-0111) is Novo Nordisk’s investigational unimolecular GLP-1 + amylin peptide agonist — not approved, not interchangeable with mono-amylin analogues or CagriSema.
- Early obesity Ph1b/2a SC data (Lancet) report secondary weight changes up to −24.3% at 36 weeks (60 mg concept) under an adherence-style estimand; primary endpoint was safety [Lancet abstract].
- Phase 2 T2D SC dose-finding (ADA 2026) reports week-36 A1C change up to −1.71%-points and weight change up to −14.6% at 40 mg vs placebo [Novo US].
- Phase 3 AMAZE obesity work is underway (e.g., AMAZE 7 SC vs sema; AMAZE 9 oral) [NCT07668414; NCT07720271].
- This page is RUO education with no SaiyanMed stock claim.
Related reading & research inquiry
- What Is Petrelintide
- What Is Eloralintide
- Eloralintide vs Cagrilintide
- Eloralintide RUO product · Cagrilintide RUO product
CTA (SKU-gated): If your laboratory needs a verified dual GLP-1/amylin reference material or wants to be notified if RUO zenagamtide/amycretin is listed after supplier COA review, contact SaiyanMed research support. We will not invent inventory on this page.
Research Use Only disclaimer
Research Use Only. Content summarizes published molecular, clinical-development, and analytical-quality information for laboratory professionals. It does not provide medical or veterinary advice, validated experimental protocols, dosing or reconstitution instructions, or authorization for in-vivo work. Animal research requires applicable institutional approvals. Zenagamtide/amycretin remains investigational as a therapeutic candidate.
Sources & further reading
- 1. Novo Nordisk U.S. — Zenagamtide Phase 2 T2D ADA 2026 (2026-06-05) — https://www.novonordisk-us.com/media/press-releases/zenagamtide-phase2-t2d-ada-2026.html
- 2. Novo Nordisk GlobeNewswire Q3 2026 (AMAZE 9 oral initiated Sep) — https://www.globenewswire.com/news-release/2026/11/04/3395015/0/en/novo-raises-full-year-outlook-on-continued-glp-1-momentum-with-third-quarter-adjusted-operating-profit-increasing-27-at-cer-to-dkk-31-720-million.html
- 3. Novo Nordisk GlobeNewswire Q1 2026 (AMAZE programme initiated) — https://www.globenewswire.com/news-release/2026/05/06/3288491/0/en/Novo-Nordisk-s-adjusted-operating-profit-reached-DKK-32-858-million-in-Q1-2026.html
- 4. ClinicalTrials.gov NCT07668414 (AMAZE 7) — https://clinicaltrials.gov/study/NCT07668414
- 5. ClinicalTrials.gov NCT07720271 (AMAZE 9) — https://clinicaltrials.gov/study/NCT07720271
- 6. ClinicalTrials.gov NCT06542874 (Ph2 T2D dose-finding NNC0487-0111) — https://clinicaltrials.gov/study/NCT06542874
- 7. Lancet amycretin SC Ph1b/2a abstract — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01185-7/abstract
- 8. Novo GlobeNewswire 2025-06-20 (SC + oral amycretin Lancet/ADA) — https://www.globenewswire.com/news-release/2025/06/20/3102977/0/en/novo-nordisk-s-subcutaneous-and-oral-amycretin-data-published-in-the-lancet-and-presented-at-ada-2025.html
- 9. NEJM CagriSema REDEFINE 1 — https://www.nejm.org/doi/full/10.1056/NEJMoa2502081
- 10. touchENDOCRINOLOGY zenagamtide insight (EASD 2026 commentary) — https://touchendocrinology.com/insight/zenagamtide-exploring-the-potential-of-dual-glp-1-and-amylin-receptor-agonism/
- 11. SaiyanMed — https://saiyanmed.com/what-is-petrelintide/ · https://saiyanmed.com/what-is-eloralintide/ · https://saiyanmed.com/eloralintide-vs-cagrilintide/ · https://saiyanmed.com/product/eloralintide/ · https://saiyanmed.com/product/cagrilintide/